Intellectual Property

Atelerix Life Sciences controls the intellectual property around a robust family of novel opioid-related therapeutics:

Three issued patents:

  • U.S. 10,881,633 (2021); 10,543,187 B2 (2020); and 10,080,732 (2018) with additional patents pending
  • Includes broad claims on therapeutic uses, novel compositions of matter, formulations, assays and processes for this entire new approach to opioid-related unmet medical needs
  • Planned international scope through PCT filing
  • Exclusive Option Agreement, Case Western Reserve University